Assessing the Role of GLP-1 Drugs in Weight Loss vs. Long-Term Risks

Understanding How GLP-1 Medications Work

To start with an obvious place, it’s helpful to understand why GLP-1 medications are blowing up the healthcare industry. There are >1 billion people worldwide who struggle with obesity.

Historically, long term medical management options have been extremely limited. Dietary changes and exercise can go a long way but typically have been only modestly effective for long-term weight loss. And of course, bariatric surgery is not an option for most people.

GLP-1 receptor agonists work by targeting naturally occurring hormones in our bodies that control appetite and metabolism. Basically, these drugs do what willpower alone has failed to do for millions of people. So why are GLP-1 drugs so revolutionary? Several reasons: Money is being funneled into researching GLP-1 because they’re proven to be successful and will likely continue to be. Insurers are beginning to reassess their position on obesity as a medical illness. For years, obesity has been treated like a choice when in reality it’s a complicated disease process. Lastly, we as a society are starting to have the conversation about weight.

What the Clinical Evidence Says About Weight Loss

Let's establish facts about Ozempic separate from what you may have heard and read in popular media sources. Semaglutide (the medication found in Ozempic and Wegovy) underwent randomized control trials involving thousands of participants. One randomized trial referred to as STEP 1 published in NEJM reported participants averaged 14.9% weight loss compared to 2.4% for placebo group over a treatment period of over one year.

Importantly, medications like Ozempic have shown promise as they work on appetite by quieting down areas of the brain linked to cravings vs. simply telling you to feel less hungry.

Some of the weight loss that occurs will come from lean mass, not fat which is something some critics of the drug highlight. But we do know the drug works. The debate is about who, when, and for what price.

The Debate Among Medical Experts

Imagine walking into any medical meeting in 20 years from now. GLP-1 drugs will be one of if not the dominant discussion topics. Here’s what I think the different expert opinions will sound like (remember those days?!) and cardiologists are going to be the ones hyping them because efficacy trials with hard outcomes show they decrease mortality and lead to better metabolic profiles. GI doctors are going to be the ones telling you about the side effects: nausea, vomiting, gastroparesis, pancreatitis that prevent some patients from continuing on the medications long-term. Psychiatrists are warning of neurological side effects we don’t know about yet, and observing decreases in addictive tendencies as well as mood alterations with these medications already. Public health scientists will be freaking out that no one is talking about health equity. After all, these medications cost over $1,000 / month without insurance and low-income communities are disproportionately affected by obesity.

Will all experts agree that GLP-1 medications are game changers? You bet. But they’ll only be game changing if we ensure proper implementation.

Public Interest and the Search for Answers

Interest in GLP-1s has also been reflected online. According to data from Google Trends and several search traffic analysis platforms, searches for GLP-1 words and semaglutide and tirzepatide in particular have increased by more than 400% over the last two years. Search interest tends to increase following announcements from celebrities, viral tweets, and media events. Popular Google searches about GLP-1s also highlight patient concerns including hair loss, muscle loss, “Ozempic face,” and what occurs when you stop taking the drugs.

The collective interest online highlights the public’s desire for transparent and thorough resources about GLP-1s that advertisements and social media videos are unable to match.

Providers have an opportunity to meet patients where they’re searching for answers.

Why Healthcare Professionals Are Watching Closely

It’s likely no surprise to hear that GLP-1 drugs topped our annual reader poll as the top health trend of the year. But did you know it also received the majority of votes when we asked an audience of healthcare professionals to predict the leading health trend of 2026?

While you could argue that’s because GLP-1 therapies are already popular, it’s also because this designation was predicted using things like pipeline announcements, current clinical trial activity, and evolving healthcare needs. For example: there are next-generation medications in development right now (called triple agonists) that act on the GLP-1 receptor, GIP receptor and glucagon receptor at the same time, and early clinical trial results show they may be even more effective than what’s currently on the market. There are oral formulations of semaglutide on the way for patients who don’t want to or can’t use injections. Hospitals and clinics across the country are starting to implement comprehensive GLP-1 programs to help patients utilize these medications while also receiving meal support, mental health resources, and exercise guidance. Even companion diagnostics, which help identify who will see the best results from which GLP-1 drug, are in development.

Balancing Benefits, Risks, and Patient Choice

One answer to that question which I think nobody can fairly object to is this: Yes. Miracles and liabilities both. The evidence strongly supports their efficacy, and specifically their cardiovascular safety no longer is that a question. But they don't have unlimited long-term safety data, and we don't know everything about how they work. Hopefully further studies will ease those concerns. For now, the best answer I can give is that they're probably safe and effective if you're one of the people who need them. But you should make sure to talk to your doctor about the potential risks and benefits.*** Preferities Based Decisions: As with any medical intervention, the decision about whether or not to take one of these drugs should be made based on...wait for it....your preferences! Patients should understand the known risks and benefits, then make an informed-decision based on their unique values and concerns.

That's why doctors should explain things and patients should kick the Terminator.***Informed Consent: Some doctors may be downplaying potential risks because they don't want patients to refuse treatment. That is unethical. Patients should be made aware of potential risks.

Conclusion

The history of GLP-1 medications is still unfolding, and the ending has not been determined.

However, what we do know is that GLP-1 drugs have opened a door that diet after diet and gastric sleeve after gastric bypass could not for good reason. Grounded in science and backed by research, GLP-1 medications are providing countless individuals around the world with access to significant weight loss and enhanced metabolic health. As we move forward with GLP-1 drugs, let’s work to embrace this pharmaceutical innovation for what it is: an opportunity to thoughtfully weigh the risks and benefits; increase accessibility while maintaining safety protocols; and, most importantly, remember there is a person on the other end of every search engine and prescription pad.